You are here

Article Text

Article menu
Download PDFPDF
Liver
Guideline review
EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis
  1. Ann J Archer1,2,
  2. Katherine J Belfield1,3,
  3. James G Orr1,
  4. Fiona H Gordon1,
  5. Kushala WM Abeysekera1,2
  1. 1 Liver Medicine, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
  2. 2 Population Health Science, University of Bristol, Bristol, UK
  3. 3 School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
  1. Correspondence to Dr Ann J Archer, Liver Medicine, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 3NU, UK; annarcher1{at}nhs.net

Abstract

The European Association for the Study of the Liver has recently published updated guidelines on the use of non-invasive tests to identify and stratify chronic liver disease. Here, we provide a summary of the key recommendations from the guideline.

  • non-alcoholic steatohepatitis
  • screening
  • hepatic fibrosis
  • alcoholic liver disease
  • liver function test

https://doi.org/10.1136/flgastro-2021-102064

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @Annie Archer, @KushAbey

    • Contributors AJA reviewed the guideline and drafted the manuscript. KB reviewed the literature and provided critical revision of the manuscript. FHG and JGO provided critical revision of the manuscript. KWMA reviewed the literature and provided critical revision of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests KWMA has received lecture honoraria from Intercept Pharma. AJA is an NIHR academic clinical fellow.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • Highlights from this issue
      Highlights from this issue
      R Mark Beattie
      Frontline Gastroenterology 2022; 13 363-364 Published Online First: 05 Aug 2022. doi: 10.1136/flgastro-2022-102279